N/A N=86 Recovery Time and Affecting Factors in Hemodialysis Patients
Dialysis; Complications · Life Quality
Primary: Post-dialysis Recovery Time — 278.02 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
N/A N=64 Treatment of Peritonitis in Automated Peritoneal Dialysis
Secondary Peritonitis
Primary: Peritonitis Resolved — 26; 29 participants — p=<0.05
N/A N=1,431 Enhancing the Cardiovascular Safety of Hemodialysis Care (Dialysafe)
Kidney Failure · End Stage Renal Disease · Hypotension
Primary: Dialysis Session Stability — 0.202; 0.199; 0.172; 0.182 Proportion of sessions
Phase 2 N=52 Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension
Intra-dialytic Hypotension
Primary: Efficacy of Mannitol Administration in Reducing the Frequency of Intra-dialytic Hypotension (Decline in Systolic Blood Pressure) During the First Three Hemodialysis…
N/A N=1,113 Renal Replacement Therapy and In-Hospital Mortality Incidence in Cardiac Surgery Associated Acute Kidney Injury
Acute Kidney Injury
Primary: Mortality — 96; 34 Participants — p=<0.0001
Phase 4 N=309 20070360 Incident Dialysis
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001
N/A N=16 Expanded Hemodialysis Versus Online Hemodiafiltration
Dialysis Related Complication · Dialysis Hypotension · Hemodialysis-Induced Symptom
Primary: Medium Molecule Clearance — 53; 59.5 ml/min — p=0.4534
N/A N=126 Blood Pressure in Dialysis Patients
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
N/A N=240 POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study
Hyperkalemia
Primary: Incidence of Pre-dialysis HK After the LIDP in <3K Dialysate Patients — 50; 37 Percent of participants
N/A N=18 Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
Complication of Extracorporeal Circulation · Renal Impairment
Primary: Renal Blood Flow (RBF) — 554; 524; 564; 558 ml per minute per 1.73 m2 body surface — p=0.638
N/A N=599 Dialysis Catheter Comparative Clinical Trial
End Stage Renal Disease
Primary: First Catheter Induced Complication — 78; 77 percentage of participants
N/A N=105 DIVINE: Dialysis Infection and Vitamin D In New England
End Stage Renal Disease
Primary: Serum 25D Level — 49.8; 38.3; 27.3 ng/ml
N/A N=164 Arteriovenous Fistula Cannulation Practices and Dialysis Adequacy
Arteriovenous Fistula · Hemodialysis · Dialysis Adequacy
Primary: Number of Fistula Needle Direction — 72; 92 Participants
N/A N=4 Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
N/A N=73 Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass
Acute Kidney Injury
Primary: Number of Participants With Negative Fluid Balance on Postop Day 1 — 21; 29 Participants
N/A N=22 Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients
End Stage Renal Disease
Primary: High Sensitivity C-reactive Protein (hsCRP) — 4.67; 15.11 mg/dl — p=0.008
Phase 3 N=277 Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)
Hepatitis B Virus Infection
Primary: The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B™ (Currently Licensed Vaccine) at Month 7 — 49; 64 Participants
N/A N=6 Intradialytic Drug Removal by Short-daily Hemodialysis
End Stage Renal Disease · Infection
Primary: Intradialytic Clearance of Levofloxacin, Gentamicin and Vancomycin in Patients Receiving Short-daily Hemodialysis — 7.2; 7.6 ml/min
N/A N=52 Vitamin D and Arteriovenous Fistulae
End-stage Renal Disease
Primary: Arteriovenous Fistulae Maturation — 50; 40 percentage of group
Phase 2 N=12 Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
Hypertension · End Stage Renal Disease
Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg
N/A N=1,075 Quality of Life and Depression in Dialysis Patients
Chronic Kidney Disease Stage 5
Primary: Change of Kidney Disease Quality of Life Short Form 1.3 (KDQOL SF 1.3) Score and Beck Depression Inventory(BDI) Score From Visit 1 Period — 1.22; -1.50; 1.62; 0.46 units…
N/A N=19 Conventional Hemodialysis vs. Short Daily Hemodialysis (6 Days / Week) and Mechanisms of Blood Pressure Control
End Stage Renal Disease
Primary: Mean Systolic Blood Pressure Over the Third Month of Each Treatment Arm — 139; 142 mm Hg
N/A N=172 Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
End Stage Renal Disease
Primary: Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 — 32.156; 17.514 percentage ratio
N/A N=46 Breaking Down Care Process and Patient-level Barriers to Arteriovenous Access Creation Prior to Hemodialysis Initiation
Chronic Kidney Disease · Chronic Kidney Disease Requiring Chronic Dialysis
Primary: Mean Scores of a Questionnaire Evaluating Patient Confidence in Navigating Vascular Access Care Pre- to Post-program Implementation — 8.0; 8.7 score on a scale — p=0.20
N/A N=10 Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis
End-Stage Renal Disease
Primary: Safety as Evaluated by Rate and Severity of Treatment-emergent AEs (TEAEs) — 1; 0; 0; 0 Participants
N/A N=26 Catheter System Feasibility Clinical Trial
Renal Insufficiency, Chronic
Primary: Number of Participants With Sufficient Patency for Clinical Access — 20 Participants
N/A N=12 Intra-abdominal Pressure in Peritoneal Dialysis Patients
Peritoneal Dialysis
Primary: Intra-Abdominal Pressure (IAP) — -0.5; -0.2; -1.2 mm Hg
Phase 2 N=24 Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
N/A N=22 Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure
Hypoplastic Left Heart Syndrome
Primary: Time to First Post-operative Negative 24 Hour Fluid Balance — 2.7; 2.67 Days